作者
Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang
发表日期
2019/11
来源
Therapeutic advances in medical oncology
卷号
11
页码范围
1758835919890286
出版商
SAGE Publications
简介
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Acquired resistance inevitably develops, with the EGFR T790M mutation comprising approximately 55% of the mechanisms of resistance following first- or second-generation EGFR-TKI therapy (e.g. gefitinib, erlotinib, afatinib, and dacomitinib). Patients without T790M are a heterogeneous group for whom platinum-based chemotherapy is currently recommended as a second-line treatment. In addition to secondary mutations in EGFR (e.g. T790M), the currently known resistance mechanisms can be classified into the following three categories: bypass pathways, downstream signaling pathways, and histologic transformations. Given the evolving knowledge and convenience of diagnosing acquired resistance mechanisms by next …
学术搜索中的文章
BC Liao, S Griesing, JCH Yang - Therapeutic advances in medical oncology, 2019